Abbreviations used in clinical trials: Difference between revisions
No edit summary |
Tag: Undo |
||
| Line 1: | Line 1: | ||
<div style="-moz-column-count:4; column-count:4;"> | <div style="-moz-column-count:4; column-count:4;"> | ||
ABI Ankle-brachial index | |||
ACC American College of Cardiology | |||
ACS Acute coronary syndrome | ACS Acute coronary syndrome | ||
| Line 25: | Line 25: | ||
ATP Adult Treatment Panel | ATP Adult Treatment Panel | ||
BMI Body mass index | BMI Body mass index | ||
BUN Blood urea nitrogen | BUN Blood urea nitrogen | ||
CABG Coronary artery bypass graft | CABG Coronary artery bypass graft | ||
| Line 55: | Line 53: | ||
CVD Cardiovascular disease | CVD Cardiovascular disease | ||
DHA Docosahexaenoic acid | DHA Docosahexaenoic acid | ||
DMC Data Monitoring Committee | DMC Data Monitoring Committee | ||
EC Independent Ethics Committee | EC Independent Ethics Committee | ||
| Line 75: | Line 71: | ||
EU European Union | EU European Union | ||
FBG Fasting blood glucose | FBG Fasting blood glucose | ||
| Line 82: | Line 77: | ||
FSH Follicle-stimulating hormone | FSH Follicle-stimulating hormone | ||
GCP Good Clinical Practice | GCP Good Clinical Practice | ||
| Line 91: | Line 85: | ||
GWAS Genome-wide association study | GWAS Genome-wide association study | ||
HbA1c Hemoglobin A1c | HbA1c Hemoglobin A1c | ||
| Line 112: | Line 105: | ||
HTG Hypertriglyceridemia | HTG Hypertriglyceridemia | ||
ICF Informed consent form | ICF Informed consent form | ||
| Line 129: | Line 121: | ||
IWRS Interactive Web Response System | IWRS Interactive Web Response System | ||
JAS Japanese Atherosclerosis Society | JAS Japanese Atherosclerosis Society | ||
LBBB Left bundle branch block | LBBB Left bundle branch block | ||
| Line 143: | Line 133: | ||
LVH Left ventricle hypertrophy | LVH Left ventricle hypertrophy | ||
MACE Major adverse coronary event | MACE Major adverse coronary event | ||
| Line 150: | Line 139: | ||
mITT Modified Intent-to-Treat | mITT Modified Intent-to-Treat | ||
NCEP National Cholesterol Education Program | NCEP National Cholesterol Education Program | ||
| Line 159: | Line 147: | ||
NSTE-ACS Non-ST-segment elevation acute coronary syndrome | NSTE-ACS Non-ST-segment elevation acute coronary syndrome | ||
O3FA Omega-3 fatty acid | O3FA Omega-3 fatty acid | ||
| Line 168: | Line 155: | ||
OR Odds ratio | OR Odds ratio | ||
PAD Peripheral arterial disease | PAD Peripheral arterial disease | ||
| Line 183: | Line 169: | ||
PVD Peripheral vascular disease | PVD Peripheral vascular disease | ||
RBC Red blood cells | RBC Red blood cells | ||
| Line 190: | Line 175: | ||
RR Relative risk | RR Relative risk | ||
SAE Serious adverse event | SAE Serious adverse event | ||
| Line 200: | Line 184: | ||
SUSAR Suspected unexpected serious adverse reaction | SUSAR Suspected unexpected serious adverse reaction | ||
TC Total cholesterol | TC Total cholesterol | ||
| Line 212: | Line 195: | ||
TIMI Thrombolysis In Myocardial Infarction | TIMI Thrombolysis In Myocardial Infarction | ||
ULN Upper limit of normal | ULN Upper limit of normal | ||
| Line 219: | Line 201: | ||
USPI United States Prescribing Information | USPI United States Prescribing Information | ||
VLDL-C Very low density lipoprotein cholesterol | VLDL-C Very low density lipoprotein cholesterol | ||
WBC White cell blood count | WBC White cell blood count | ||
Latest revision as of 17:43, 27 October 2019
ABI Ankle-brachial index
ACC American College of Cardiology
ACS Acute coronary syndrome
AE Adverse event
AHA American Heart Association
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AP Angina pectoris
apo B Apolipoprotein B
APOC3 Apolipoprotein C3
AST Aspartate aminotransferase
ATP Adult Treatment Panel
BMI Body mass index
BUN Blood urea nitrogen
CABG Coronary artery bypass graft
CAD Coronary artery disease
CBC Complete blood count
CEC Clinical Endpoint Committee
CHD Coronary heart disease
CHF Congestive heart failure
CI Confidence interval
CK-MB Creatine kinase-MB fraction
CrCL Creatinine clearance
CRF Case report form
CV Cardiovascular
CVD Cardiovascular disease
DHA Docosahexaenoic acid
DMC Data Monitoring Committee
EC Independent Ethics Committee
ECG Electrocardiogram
EDC Electronic data capture
eGRF Estimated glomerular filtration rate
EPA Eicosapentaenoic acid
Ethyl-EPA ethyl eicosapentaenoic acid
EU European Union
FBG Fasting blood glucose
FDA United States Food and Drug Administration
FSH Follicle-stimulating hormone
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GMP Good Manufacturing Practice
GWAS Genome-wide association study
HbA1c Hemoglobin A1c
Hct Hematocrit
HDL-C High-density lipoprotein cholesterol
HF Heart failure
Hgb Hemoglobin
HIV Human immunodeficiency virus
HR Hazard ratio
hs-CRP High-sensitivity C-reactive protein
hsTnT High-sensitivity troponin T
HTG Hypertriglyceridemia
ICF Informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IFCC International Federation of Clinical Chemistry
IMP Investigational medicinal product
IQR Interquartile range
IRB Institutional Review Board
ITT Intent-to-Treat
IWRS Interactive Web Response System
JAS Japanese Atherosclerosis Society
LBBB Left bundle branch block
LDL-C Low-density lipoprotein cholesterol
LOE Lack of efficacy
LpPLA2 Lipoprotein-associated phospholipase A2
LVH Left ventricle hypertrophy
MACE Major adverse coronary event
MI Myocardial infarction or mitral insufficiency
mITT Modified Intent-to-Treat
NCEP National Cholesterol Education Program
NGSP National Glycohemoglobin Standardization Program
NMR Nuclear magnetic resonance
NSTE-ACS Non-ST-segment elevation acute coronary syndrome
O3FA Omega-3 fatty acid
ODIS Off drug in stud y OGTT Oral glucose tolerance test
OR Odds ratio
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin kexin 9
PH Proportional hazard
PI Principal Investigator
PP Per protocol
PVD Peripheral vascular disease
RBC Red blood cells
RLP-C Remnant lipoprotein cholesterol
RR Relative risk
SAE Serious adverse event
SAP Statistical Analysis Plan
SC Steering Committee
SPC Summary of Product Characteristics
SUSAR Suspected unexpected serious adverse reaction
TC Total cholesterol
TEAE Treatment-emergent adverse event
TG Triglycerides
TIA Transient Ischemic Attack
TIMI Thrombolysis In Myocardial Infarction
ULN Upper limit of normal
US United States
USPI United States Prescribing Information
VLDL-C Very low density lipoprotein cholesterol
WBC White cell blood count